Plasma Matrix Metalloproteinase-1 as a Prognostic Biomarker in Oral Cavity Squamous Cell Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Howard A, Agrawal N, Gooi Z. Lip and oral cavity squamous cell carcinoma. Hematol Oncol Clin North Am. 2021;35(5):895–911. doi:10.1016/j.hoc.2021.05.003
   PubMed Web of Science ®Google Scholar
• Chamoli A, Gosavi AS, Shirwadkar UP, et al. Overview of oral cavity squamous cell carcinoma: risk factors, mechanisms, and diagnostics. Oral Oncol. 2021;121:105451. doi:10.1016/j.oraloncology.2021.105451
   PubMed Web of Science ®Google Scholar
• Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer. 1999;85(5):1018–1025. doi:10.1002/(SICI)1097-0142(19990301)85:5<1018::AID-CNCR2>3.0.CO;2-R
   PubMed Web of Science ®Google Scholar
• Bhatavdekar JM, Patel DD, Vora HH, Balar DB. Circulating prolactin and TPS in monitoring the clinical course of male patients with metastatic tongue cancer: a preliminary study. Anticancer Res. 1993;13(1):237–240.
   PubMed Web of Science ®Google Scholar
• Yen TC, Lin WY, Kao CH, Cheng KY, Wang SJ. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol Allied Sci. 1998;23(1):82–86. doi:10.1046/j.1365-2273.1998.00101.x
   PubMed Web of Science ®Google Scholar
• Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N. Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. J Craniomaxillofac Surg. 1998;26(4):243–248. doi:10.1016/s1010-5182(98)80020-6
   PubMed Web of Science ®Google Scholar
• Pardo A, Selman M. MMP-1: the elder of the family. Int J Biochem Cell Biol. 2005;37(2):283–288. doi:10.1016/j.biocel.2004.06.017
   PubMed Web of Science ®Google Scholar
• Maciejczyk M, Pietrzykowska A, Zalewska A, Knaś M, Daniszewska I. The significance of matrix metalloproteinases in oral diseases. Adv Clin Exp Med. 2016;25(2):383–390. doi:10.17219/acem/30428
   PubMed Web of Science ®Google Scholar
• Yen CY, Chen CH, Chang CH, et al. Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. Biomarkers. 2009;14(4):244–249. doi:10.1080/13547500902829375
   PubMed Web of Science ®Google Scholar
• An HJ, Lee YJ, Hong SA, et al. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer. Pathol Res Pract. 2016;212(5):357–364. doi:10.1016/j.prp.2015.11.014
   PubMed Web of Science ®Google Scholar
• Boström P, Söderström M, Vahlberg T, et al. MMP-1 expression has an independent prognostic value in breast cancer. BMC Cancer. 2011;11(1):348. doi:10.1186/1471-2407-11-348
   PubMed Web of Science ®Google Scholar
• Yang R, Xu Y, Li P, et al. Combined upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 predicts unfavorable prognosis in human nasopharyngeal carcinoma. Onco Targets Ther. 2013;6:1139–1146. doi:10.2147/ott.S50389
   PubMed Web of Science ®Google Scholar
• Chang YT, Chu LJ, Liu YC, et al. Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer. Cancers. 2020;12(8). doi:10.3390/cancers12082273
   Web of Science ®Google Scholar
• Jonsson A, Falk P, Angenete E, Hjalmarsson C, Ivarsson ML. Plasma MMP-1 expression as a prognostic factor in colon cancer. J Surg Res. 2021;266:254–260. doi:10.1016/j.jss.2021.04.021
   PubMed Web of Science ®Google Scholar
• Li M, Xiao T, Zhang Y, et al. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer. 2010;69(3):341–347. doi:10.1016/j.lungcan.2009.12.007
   PubMed Web of Science ®Google Scholar
• Kulić A, Dedić Plavetić N, Vrbanec J, Sirotković-Skerlev M. Low serum MMP-1 in breast cancer: a negative prognostic factor? Biomarkers. 2012;17(5):416–421. doi:10.3109/1354750x.2012.678885
   PubMed Web of Science ®Google Scholar
• Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–1316. doi:10.1097/JTO.0b013e3181ec173d
   PubMed Web of Science ®Google Scholar
• Herszényi L, Hritz I, Lakatos G, Varga MZ, Tulassay Z. The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci. 2012;13(10):13240–13263. doi:10.3390/ijms131013240
   PubMed Web of Science ®Google Scholar
• Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta. 2010;1803(1):55–71. doi:10.1016/j.bbamcr.2010.01.003
   PubMed Web of Science ®Google Scholar
• Bassiouni W, Ali MAM, Schulz R. Multifunctional intracellular matrix metalloproteinases: implications in disease. FEBS J. 2021;288(24):7162–7182. doi:10.1111/febs.15701
   PubMed Web of Science ®Google Scholar
• Airola K, Karonen T, Vaalamo M, et al. Expression of collagenases-1 and −3 and their inhibitors TIMP-1 and −3 correlates with the level of invasion in malignant melanomas. Br J Cancer. 1999;80(5–6):733–743. doi:10.1038/sj.bjc.6690417
   PubMed Web of Science ®Google Scholar
• Winer A, Adams S, Mignatti P. Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes. Mol Cancer Ther. 2018;17(6):1147–1155. doi:10.1158/1535-7163.Mct-17-0646
   PubMed Web of Science ®Google Scholar
• Cathcart JM, Cao J. Inhibitors: past, present and future. Front Biosci. 2015;20(7):1164–1178. doi:10.2741/4365
   Web of Science ®Google Scholar
• Rezaei F, Imani MM, Lopez-Jornet P, Sadeghi M. Estimation of serum and salivary matrix metalloproteinase levels in oral squamous cell carcinoma patients: a systematic review and meta-analysis. Postepy Dermatol Alergol. 2021;38(2):106–114. doi:10.5114/ada.2021.104285
   PubMed Web of Science ®Google Scholar
• Brinckerhoff CE, Rutter JL, Benbow U. Interstitial collagenases as markers of tumor progression. Clin Cancer Res. 2000;6(12):4823–4830.
   PubMed Web of Science ®Google Scholar
• Hilska M, Roberts PJ, Collan YU, et al. Prognostic significance of matrix metalloproteinases-1, −2, −7 and −13 and tissue inhibitors of metalloproteinases-1, −2, −3 and −4 in colorectal cancer. Int J Cancer. 2007;121(4):714–723. doi:10.1002/ijc.22747
   PubMed Web of Science ®Google Scholar
• Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol. 1999;12(7):669–674.
   PubMed Web of Science ®Google Scholar
• Inoue T, Yashiro M, Nishimura S, et al. Matrix metalloproteinase-1 expression is a prognostic factor for patients with advanced gastric cancer. Int J Mol Med. 1999;4(1):73–77. doi:10.3892/ijmm.4.1.73
   PubMed Web of Science ®Google Scholar
• Poola I, DeWitty RL, Marshalleck JJ, Bhatnagar R, Abraham J, Leffall LD. Identification of MMP-1 as a putative breast cancer predictive marker by global gene expression analysis. Nat Med. 2005;11(5):481–483. doi:10.1038/nm1243
   PubMed Web of Science ®Google Scholar
• Gouyer V, Conti M, Devos P, et al. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer. 2005;103(8):1676–1684. doi:10.1002/cncr.20965
   PubMed Web of Science ®Google Scholar
• Lin TS, Chiou SH, Wang LS, et al. Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer. Oncol Rep. 2004;12(4):717–723.
   PubMed Web of Science ®Google Scholar
• Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J, Mellon JK. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res. 2001;7(11):3450–3456.
   PubMed Web of Science ®Google Scholar
• Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005;11(14):5158–5166. doi:10.1158/1078-0432.Ccr-04-2478
   PubMed Web of Science ®Google Scholar
• Tao YS, Ma XY, Chai DM, et al. Overexpression of MMP-1 and VEGF-C is associated with a less favorable prognosis in esophageal squamous cell carcinoma. Oncol Res Treat. 2012;35(11):651–656. doi:10.1159/000343637
   Web of Science ®Google Scholar
• Fujimoto D, Hirono Y, Goi T, Katayama K, Yamaguchi A. Prognostic value of protease-activated receptor-1 (PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer. Anticancer Res. 2008;28(2a):847–854.
   PubMed Web of Science ®Google Scholar
• Buergy D, Weber T, Maurer GD, et al. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies. Int J Cancer. 2009;125(4):894–901. doi:10.1002/ijc.24462
   PubMed Web of Science ®Google Scholar
• Luukkaa H, Klemi P, Hirsimäki P, et al. Matrix metalloproteinase (MMP)-1, −9 and −13 as prognostic factors in salivary gland cancer. Acta Otolaryngol. 2008;128(4):482–490. doi:10.1080/00016480801922895
   PubMed Web of Science ®Google Scholar
• Fan HX, Chen Y, Ni BX, et al. Expression of MMP-1/PAR-1 and patterns of invasion in oral squamous cell carcinoma as potential prognostic markers. Onco Targets Ther. 2015;8:1619–1626. doi:10.2147/ott.S84561
   PubMed Web of Science ®Google Scholar
• Lassig AAD, Joseph AM, Lindgren BR, Yueh B. Association of oral cavity and oropharyngeal cancer biomarkers in surgical drain fluid with patient outcomes. JAMA Otolaryngol Head Neck Surg. 2017;143(7):670–678. doi:10.1001/jamaoto.2016.3595
   PubMed Web of Science ®Google Scholar
• Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients with oral cancer. Head Neck. 2007;29(6):564–572. doi:10.1002/hed.20561
   PubMed Web of Science ®Google Scholar